Gastric adenocarcinoma and colorectal adenocarcinoma
Conditions
Interventions
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years; 2.Signed informed consent to participate in the program; 3.ECOG score <= 1; 4.Gastric adenocarcinoma/colorectal adenocarcinoma diagnosed by histopathology; 5.No family history of hereditary tumors; 6.Anti-tumor therapy naive; 7.Sufficient surgical or biopsy tissue from the primary site that meets the requirements for submission for examination; 8.Sufficient peripheral blood specimens that meet the requirements for submission for examination;
Exclusion criteria
Exclusion criteria: 1.People at high risk for hereditary colorectal adenocarcinoma, i.e., members of families with a history of gastrointestinal tumors, familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal adenocarcinoma (HNPCC/LS), and P-J syndrome. 2.History of chronic metabolic and inflammatory diseases such as uncontrolled hypertension, diabetes mellitus, chronic viral hepatitis, and inflammatory bowel disease; 3.Other malignancies known to have progressed or required treatment within the past 5 years, except radically treated basal cell and squamous skin cancers; 4.History of oral or intravenous use of broad-spectrum antibiotics and probiotic preparations within the last 1 month; 5.Routine use of immunosuppressive drugs in the last 6 months; 6.Long-term use of other drugs that may affect the body's metabolism, such as hormones; 7.Inability or unwillingness to cooperate with follow-up visits and related examinations; 8.Condition that prevents from eating normally or requires medication or enemas to pass stools. 9.Have a mental illness or other serious cardiovascular disease; 10.Pregnant or breastfeeding or planning to become pregnant within one year; 11.Currently participating in an interventional clinical study or receiving research treatment that affects patient treatment decisions; 12.Any concurrent severe and/or poorly controlled medical condition that, in the judgment of the investigator, may interfere with the patient's participation in the study or interfere with the results of the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Disease Free Survival;Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactJing Sun
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed